Regulatory Reliance under Decreto 892/2025 and Disposición 236/2026

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Decreto 892/2025 establishes the general framework for international regulatory reliance, and Disposición ANMAT 236/2026 (published February 6, 2026 in the Official Gazette, effective 30 days after publication) implements it within ANMAT’s area of competence. Together the two instruments restructure how low and medium-risk foreign products enter Argentina.

The core move: for Class I and Class II medical devices and Group A and B IVD that do not require cold chain — seven categories of foreign products in total — a prior sworn notification (notificación previa en forma de declaración jurada) replaces the traditional prior technical review. Where the product already holds marketing authorization from a reference-country authority and a free sale certificate with a validity of no more than 24 months is submitted, exemption from Argentine local testing is available. Class III/IV high-risk devices do not qualify for this channel.

The practical reach of the regime is broad but bounded. It covers seven categories of foreign products, all of them at the lower end of the risk spectrum, and it converts what used to be a prior technical evaluation into a prior sworn notification supported by reference-country documents. It does not cover Class III/IV devices, it does not waive GMP obligations, and it does not replace the product registration pathways described elsewhere — it sits alongside them at the import and commercialization stage, adding one more layer that must be planned rather than assumed.

2. Legal basis

The instruments below define the reliance framework, the notification regime, its exemption from local testing, and the penalties that back it.

InstrumentReference / numberPublication dateProvisions
International regulatory reliance frameworkDecreto 892/20252025Full text; Annex I (list of reference countries)
Notification regime for import and commercialization of low and medium-risk productsDisposición ANMAT 236/2026Published February 6, 2026, effective 30 days after publicationScope provisions; local-testing exemption provisions; penalty provisions
National Health Products LawLey 16.463Enacted 1964, currently in forcePenalty provisions (cited by 236/2026)
Argentine Food CodeLey 18.284Currently in forcePenalty provisions (cited by 236/2026)
Import facilitation for Class I/II productsDisposición ANMAT 4446/2025Published June 24, 2025, effective 30 days after publicationImport-stage provisions

3. Expert insights

Insight 1: this is the first time Argentina has recognized reference-country marketing authorizations at the institutional level. Previously, foreign approvals could serve only as supporting evidence, and ANMAT still reviewed independently. After 236/2026, a reference-country marketing authorization can, where conditions are met, directly substitute a substantial part of the local technical evaluation. This change moves Argentina toward the regulatory convergence position of the larger developed markets.

Insight 2: the gate to the channel is the certificate, not product performance. The only variable that determines whether the fast channel is open is whether a free sale certificate issued by a reference-country authority can be provided, with a validity of no more than 24 months. For companies holding only an NMPA export sales certificate from China, the channel is essentially unreachable — this is the single most important fact to establish early in planning.

Insight 3: what is relaxed at the front end is tightened at the back end. 236/2026 provides that violations will trigger investigation and penalties under Ley 16.463 and Ley 18.284, and precautionary measures may be taken under Decreto 341/92. ANMAT is shifting regulatory resources from review to post-market audit, sampling and market surveillance; a company that cannot produce the reference-country documents on request may see its declaration retroactively invalidated.

Operating under the notification regime therefore demands a different working posture from the traditional review: instead of convincing an examiner once, the company must be able to substantiate its declaration continuously, on request, for as long as the product remains on the market. The recommendations below are ordered so that feasibility is established first, the document chain second, and the standing monitoring obligations third.

4. Practical recommendations

  1. First run a channel-feasibility assessment. Check item by item the product category (Class I/II devices or cold-chain-free Group A/B IVD) and the holding of reference-country marketing authorization; both must be present, and either alone is insufficient.
  2. Build the CFS legalization chain early. Free sale certificate issued by the reference-country authority → apostille or consular legalization → certified Spanish translation; all three steps must be completed before filing, and the certificate’s validity must be confirmed as no more than 24 months.
  3. Establish a traceable document retention system. After the declaration is submitted, the reference-country documents must be retrievable at any time. Set up a dedicated file and designate a custodian.
  4. Assess the import stage in parallel. 236/2026 addresses import and commercialization eligibility, while Disposición 4446/2025 addresses exemption from batch-by-batch prior import authorization; the two apply together and cannot substitute for each other.

5. Verification checklist

Confirm each item below before relying on the 236/2026 channel.

  • □ The product has been confirmed to fall within the seven categories covered by 236/2026
  • □ Marketing authorization from a reference-country authority has been confirmed
  • □ The CFS validity is no more than 24 months and the legalization chain is complete
  • □ The Spanish translation is by a certified official or sworn translator
  • □ A retention and retrieval mechanism for reference-country documents is in place
  • □ The import-stage requirements under 4446/2025 have been confirmed in parallel

Because the regime depends on documents that expire — the free sale certificate above all — this checklist should be re-run on a calendar basis, not only at filing. An expired certificate silently converts a compliant declaration into an indefensible one, and the exposure persists for as long as the product remains on the Argentine market under the declaration.

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly-owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and labeling localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the developments of regulatory authorities worldwide. All published content follows the drafting standard of conclusions first, traceable legal basis, and verifiable figures. For an Argentina or MERCOSUR market-access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail